Jochen Greiner

Oct 10, 2024 | mdpi.com | Jochen Greiner |Eithar Mohamed |Daniel Fletcher |Patrick J Schuler

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 20, 2024 | preprints.org | Jochen Greiner |Eithar Mohamed |Daniel Fletcher |Patrick J Schuler

PreprintReviewVersion 1This version is not peer-reviewedVersion 1: Received: 19 June 2024 / Approved: 20 June 2024 / Online: 20 June 2024 (08:30:47 CEST)Greiner, J.; Mohamed, E.; Fletcher, D. M.; Schuler, P. J.; Schrezenmeier, H.; Götz, M.; Guinn, B.-A. Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AML. Preprints 2024, 2024061388. https://doi.org/10.20944/preprints202406.1388.v1Greiner, J.; Mohamed, E.; Fletcher, D. M.; Schuler, P. J.; Schrezenmeier, H.; Götz, M.; Guinn, B.-A.

Apr 27, 2024 | nature.com | Luca Fischer |Linmiao Jiang |Stephan Stilgenbauer |Ullrich Graeven |Jochen Greiner |Eric Durot | +3 more

AbstractThe therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT).